1. Hyperforin inhibits cancer invasion and metastasis.
- Author
-
Donà M, Dell'Aica I, Pezzato E, Sartor L, Calabrese F, Della Barbera M, Donella-Deana A, Appendino G, Borsarini A, Caniato R, and Garbisa S
- Subjects
- Adenocarcinoma blood, Adenocarcinoma drug therapy, Adenocarcinoma pathology, Animals, Apoptosis drug effects, Bridged Bicyclo Compounds, Cell Division drug effects, Cell Survival drug effects, Colonic Neoplasms blood, Colonic Neoplasms drug therapy, Colonic Neoplasms pathology, Cyclohexylamines blood, Cyclohexylamines pharmacology, Enzyme Activation drug effects, Fibrosarcoma blood, Fibrosarcoma drug therapy, Fibrosarcoma pathology, Gelatinases biosynthesis, Humans, Lung Neoplasms blood, Lung Neoplasms drug therapy, Lung Neoplasms secondary, Male, Melanoma, Experimental blood, Melanoma, Experimental drug therapy, Melanoma, Experimental pathology, Mice, Mice, Inbred BALB C, Mitogen-Activated Protein Kinase 1 metabolism, Mitogen-Activated Protein Kinase 3, Mitogen-Activated Protein Kinases metabolism, Neoplasm Invasiveness, Neoplasm Metastasis, Neoplasms blood, Neoplasms pathology, Neuroblastoma blood, Neuroblastoma drug therapy, Neuroblastoma pathology, Phloroglucinol analogs & derivatives, Quaternary Ammonium Compounds blood, Quaternary Ammonium Compounds pharmacology, Serine Endopeptidases metabolism, Terpenes blood, Neoplasms drug therapy, Terpenes pharmacology
- Abstract
Hyperforin (Hyp), the major lipophilic constituent of St. John's wort, was assayed as a stable dicyclohexylammonium salt (Hyp-DCHA) for cytotoxicity and inhibition of matrix proteinases, tumor invasion, and metastasis. Hyp-DCHA triggered apoptosis-associated cytotoxic effect in both murine (C-26, B16-LU8, and TRAMP-C1) and human (HT-1080 and SK-N-BE) tumor cells; its effect varied, with B16-LU8, HT-1080, and C-26 the most sensitive (IC50 = 5 to 8 micromol/L). At these concentrations, a marked and progressive decline of growth was observed in HT-1080 cells, whereas untransformed endothelial cells were only marginally affected. Hyp-DCHA inhibited in a dose-dependent and noncompetitive manner various proteinases instrumental to extracellular matrix degradation; the activity of leukocyte elastase was inhibited the most (IC50 = 3 micromol/L), followed by cathepsin G and urokinase-type plasminogen activator, whereas that of the matrix metalloproteinases (MMPs) 2 and 9 showed an IC50 > 100 micromol/L. Nevertheless, inhibition of extracellular signal-regulated kinase 1/2 constitutive activity and reduction of MMP-2 and MMP-9 secretion was triggered by 0.5 micromol/L Hyp-DCHA to various degrees in different cell lines, the most in C-26. Inhibition of C-26 and HT-1080 cell chemoinvasion (80 and 54%, respectively) through reconstituted basement membrane was observed at these doses. Finally, in mice that received i.v. injections of C-26 or B16-LU8 cells, daily i.p. administration of Hyp-DCHA-without reaching tumor-cytotoxic blood levels-remarkably reduced inflammatory infiltration, neovascularization, lung weight (-48%), and size of experimental metastases with C-26 (-38%) and number of lung metastases with B16-LU8 (-22%), with preservation of apparently healthy and active behavior. These observations qualify Hyp-DCHA as an interesting lead compound to prevent and contrast cancer spread and metastatic growth.
- Published
- 2004
- Full Text
- View/download PDF